{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:21:41Z","timestamp":1792686101821,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ejim.2023.08.019","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T08:09:57Z","timestamp":1693210197000},"page":"84-92","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Renin\u2010angiotensin-aldosterone system inhibitors and mortality risk in elderly patients with atrial fibrillation. Insights from the nationwide START registry"],"prefix":"10.1016","volume":"119","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-5903","authenticated-orcid":false,"given":"Danilo","family":"Menichelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9185-2046","authenticated-orcid":false,"given":"Emilia","family":"Antonucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4327-9561","authenticated-orcid":false,"given":"Gualtiero","family":"Palareti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2265-7455","authenticated-orcid":false,"given":"Pasquale","family":"Pignatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6357-5213","authenticated-orcid":false,"given":"Daniele","family":"Pastori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2023.08.019_bib0001","doi-asserted-by":"crossref","first-page":"e13070","DOI":"10.1111\/ijcp.13070","article-title":"Epidemiology of atrial fibrillation","volume":"72","author":"Zulkifly","year":"2018","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ejim.2023.08.019_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-049933","article-title":"Do baseline characteristics and treatments account for geographical disparities in the outcomes of patients with newly diagnosed atrial fibrillation? The prospective GARFIELD-AF registry","volume":"12","author":"Fox","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.ejim.2023.08.019_bib0003","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ijcard.2018.02.051","article-title":"Risk factors for new-onset atrial fibrillation: a focus on Asian populations","volume":"261","author":"Li","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.ejim.2023.08.019_bib0004","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehz234","article-title":"Long-term blood pressure trajectories and incident atrial fibrillation in women and men: the Tromso study","volume":"41","author":"Sharashova","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.08.019_bib0005","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/ajh\/hpx013","article-title":"Hypertension and atrial fibrillation: an intimate association of epidemiology, pathophysiology, and outcomes","volume":"30","author":"Dzeshka","year":"2017","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ejim.2023.08.019_bib0006","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCRESAHA.117.311402","article-title":"Hypertension and atrial fibrillation: doubts and certainties from basic and clinical studies","volume":"122","author":"Verdecchia","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.ejim.2023.08.019_bib0007","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/jhh.2017.6","article-title":"Renin-angiotensin blockade in atrial fibrillation: where are we now?","volume":"31","author":"Shahid","year":"2017","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.ejim.2023.08.019_bib0008","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ajh\/hpx135","article-title":"Hypertension and atrial fibrillation: balancing stroke and bleeding risks","volume":"30","author":"Esteve-Pastor","year":"2017","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.ejim.2023.08.019_bib0009","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2023.08.019_bib0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11739-015-1326-1","article-title":"Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score","volume":"11","author":"Pastori","year":"2016","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.ejim.2023.08.019_bib0011","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.ejim.2023.08.019_bib0012","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejim.2020.12.011","article-title":"The Atrial fibrillation Better Care (ABC) pathway and cardiac complications in atrial fibrillation: a potential sex-based difference. The ATHERO-AF study","volume":"85","author":"Pastori","year":"2021","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2023.08.019_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0124719","article-title":"The Italian START-register on anticoagulation with focus on atrial fibrillation","volume":"10","author":"Antonucci","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejim.2023.08.019_bib0014","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.amjcard.2020.08.009","article-title":"Cardiovascular events and mortality in patients with atrial fibrillation and anemia (from the Fushimi AF Registry)","volume":"134","author":"An","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ejim.2023.08.019_bib0015","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.08.019_bib0016","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S0195-668X(02)00700-5","article-title":"The EuroHeart failure survey programme\u2013a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment","volume":"24","author":"Komajda","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.08.019_bib0017","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.mayocp.2020.06.057","article-title":"Long-term risk of major adverse cardiac events in atrial fibrillation patients on direct oral anticoagulants","volume":"96","author":"Pastori","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejim.2023.08.019_bib0018","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/europace\/euac225","article-title":"Short- and long-term risk of atrial fibrillation recurrence after first time ablation according to body mass index: a nationwide Danish cohort study","volume":"25","author":"Tonnesen","year":"2023","journal-title":"Europace"},{"key":"10.1016\/j.ejim.2023.08.019_bib0019","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/ehjqcco\/qcab028","article-title":"GARFIELD-AF risk score for mortality, stroke, and bleeding within 2 years in patients with atrial fibrillation","volume":"8","author":"Fox","year":"2022","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"10.1016\/j.ejim.2023.08.019_bib0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(12)60520-0","article-title":"Erectile dysfunction","volume":"381","author":"Shamloul","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2023.08.019_bib0021","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/fcp.12313","article-title":"The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case\/noncase study in VigiBase","volume":"31","author":"Alharbi","year":"2017","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.ejim.2023.08.019_bib0022","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","article-title":"Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients","volume":"33","author":"van Vark","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2023.08.019_bib0023","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.005165","article-title":"Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are associated with improved outcome but do not prevent new-onset atrial fibrillation after acute myocardial infarction","volume":"6","author":"Batra","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2023.08.019_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD009096.pub2","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","author":"Li","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2023.08.019_bib0025","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","article-title":"Comparative first-line effectiveness and safety of ACE (Angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: a multinational cohort study","volume":"78","author":"Chen","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.ejim.2023.08.019_bib0026","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jacc.2018.01.058","article-title":"Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use?","volume":"71","author":"Messerli","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2023.08.019_bib0027","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12872-022-02580-2","article-title":"Impact of renin-angiotensin-aldosterone-system inhibitor drugs on mortality in patients with atrial fibrillation and hypertension","volume":"22","author":"Xu","year":"2022","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ejim.2023.08.019_bib0028","first-page":"750","article-title":"Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China","volume":"17","author":"Lyu","year":"2020","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.ejim.2023.08.019_bib0029","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1093\/europace\/euab065","article-title":"European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel","year":"2021","journal-title":"Europace"},{"key":"10.1016\/j.ejim.2023.08.019_bib0030","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nrcardio.2010.103","article-title":"Atrial fibrillation: blockade of the renin-angiotensin system in atrial fibrillation","volume":"7","author":"Kuzniatsova","year":"2010","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ejim.2023.08.019_bib0031","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2003.07.014","article-title":"Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease","volume":"42","author":"Boldt","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2023.08.019_bib0032","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1177\/1753944708092111","article-title":"Atrial fibrillation and renin-angiotensin system","volume":"2","author":"Serra","year":"2008","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.ejim.2023.08.019_bib0033","doi-asserted-by":"crossref","first-page":"e13771","DOI":"10.1111\/ijcp.13771","article-title":"Atrial fibrillation pattern, left atrial diameter and risk of cardiovascular events and mortality. A prospective multicenter cohort study","volume":"75","author":"Menichelli","year":"2021","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ejim.2023.08.019_bib0034","doi-asserted-by":"crossref","first-page":"31042","DOI":"10.1038\/srep31042","article-title":"Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation","volume":"6","author":"Hamatani","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejim.2023.08.019_bib0035","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/1753944716642677","article-title":"Cardiac remodelling and RAS inhibition","volume":"10","author":"Ferrario","year":"2016","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.ejim.2023.08.019_bib0036","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/01.RES.0000183735.09871.61","article-title":"A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation","volume":"97","author":"Kim","year":"2005","journal-title":"Circ Res"},{"key":"10.1016\/j.ejim.2023.08.019_bib0037","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1160\/TH14-07-0571","article-title":"Serum NOX2 and urinary isoprostanes predict vascular events in patients with atrial fibrillation","volume":"113","author":"Pignatelli","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ejim.2023.08.019_bib0038","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.jacc.2017.07.743","article-title":"Relationship of PCSK9 and urinary thromboxane excretion to cardiovascular events in patients with atrial fibrillation","volume":"70","author":"Pastori","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2023.08.019_bib0039","article-title":"Adenosine diphosphate-induced platelet aggregation might contribute to poor outcomes in atrial fibrillation-related ischemic stroke","author":"Choi","year":"2013","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.ejim.2023.08.019_bib0040","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.mayocp.2018.10.022","article-title":"Integrated care management of patients with atrial fibrillation and risk of cardiovascular events: the ABC (Atrial fibrillation better care) pathway in the ATHERO-AF study cohort","volume":"94","author":"Pastori","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejim.2023.08.019_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2019.02.002","article-title":"Update and unmet needs on the use of nonvitamin K oral anticoagulants for stroke prevention in patients with atrial fibrillation","volume":"46","author":"Menichelli","year":"2021","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.ejim.2023.08.019_bib0042","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/jce.14898","article-title":"Associations of anemia with stroke, bleeding, and mortality in atrial fibrillation: a systematic review and meta-analysis","volume":"32","author":"Tu","year":"2021","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.ejim.2023.08.019_bib0043","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/jth.12874","article-title":"Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation: insights from the RE-LY trial","volume":"13","author":"Westenbrink","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ejim.2023.08.019_bib0044","doi-asserted-by":"crossref","first-page":"857","DOI":"10.5152\/AnatolJCardiol.2022.2426","article-title":"Anticoagulant treatment in patients with atrial fibrillation and chronic kidney disease: practical issues","volume":"26","author":"Matusik","year":"2022","journal-title":"Anatol J Cardiol"},{"key":"10.1016\/j.ejim.2023.08.019_bib0045","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12872-023-03236-5","article-title":"Clinical benefits and risks of anticoagulation therapy according to the degree of chronic kidney disease in patients with atrial fibrillation","volume":"23","author":"Cho","year":"2023","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.ejim.2023.08.019_bib0046","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/europace\/euac059","article-title":"Effects of intensive blood pressure control on cardiovascular and cognitive outcomes in patients with atrial fibrillation: insights from the SPRINT trial","volume":"24","author":"Jiang","year":"2022","journal-title":"Europace"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523003035?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620523003035?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:40:28Z","timestamp":1760607628000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620523003035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":46,"alternative-id":["S0953620523003035"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2023.08.019","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Renin\u2010angiotensin-aldosterone system inhibitors and mortality risk in elderly patients with atrial fibrillation. Insights from the nationwide START registry","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2023.08.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}